Abstract 1359: Identification of a novel hypermethylated tumor suppressor gene in human bladder cancer

Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Bladder cancer is the sixth most common cancer in the world and the incidence is particularly high in southwestern Taiwan. Although bladder cancer patients have a low mortality rate, long term follow-up with repeated cystoscopy is required due to the high recurrence nature of the tumor. Therefore, a non-invasive detection assay is urgently required for bladder cancer patients. Aberrant promoter hypermethylation which is considered as a hallmark of cancer for over a decade, plays an important role in controlling cancer progression. Nevertheless, detection of promoter hypermethylation in bodily fluid has been implicated as a non-invasive and sensitive tool for cancer diagnosis. We aim to identify novel markers that are hypermethylated in bladder cancer. In this regard, by using illumina 27K CpG island methylation array, we identified several novel targets that are hypermethylated in 7 bladder cancer patient samples but not in primary normal human urothelim. Combined bisulfite restriction analysis (COBRA) and bisulphite pyrosequencing confirmed the array result in bladder cancer cell lines. Further, bisulphite pyrosequencing demonstrated that a significantly higher methylation level of those targets in cancer samples with higher histological grade (P < 0.05) and pathological stage (P < 0.05). The potential of non-invasive diagnosis of bladder cancer detection by using the methylation of these targets in voided urine samples is under-way. The tumor suppressive function of these methylated targets in bladder cancer deserves further investigation. Citation Format: Chia-Ming Yeh, Pi-Che Chen, Wen-Yu Huang, Cheng-Huang Shen, Cheng-Da Hsu, Michael Wy Chan. Identification of a novel hypermethylated tumor suppressor gene in human bladder cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1359. doi:10.1158/1538-7445.AM2014-1359